Efficacy of the PARP inhibitor veliparib with carboplatin or as a single agent in patients with germline BRCA1- or BRCA2-associated metastatic breast cancer: California Cancer Consortium trial NCT01149083.
Clinical Cancer Research.
Times cited: 2
Grading dermatologic adverse events of cancer treatments: The common terminology criteria for adverse events version 4.0.
Journal of the American Academy of Dermatology.
Times cited: 70